Bristol Myers Squibb (BMY) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Bristol Myers Squibb (BMY)

64.72

+0.57 (0.89%)

as of Aug 7, 2026, 8:00:00 pm Market Open.

160 watching

Investor Insights

Aug 9, 2026, 12:00 am

This summary was created by AI, based on 8 opinions in the last 12 months.

Bristol Myers Squibb (BMY) has received mixed reviews from various experts, reflecting a combination of cautious optimism and disappointment regarding its drug pipeline and overall performance. Highlighted is the stock's impressive +19% growth this year, alongside its strong cash flow generation expected to reach $11 billion this year and $15 billion by 2027, all while offering a substantial dividend yield over 4%. However, concerns have been raised about the underwhelming sales performance of the Cobenfy drug, with some experts recommending a more cautious approach as they await positive news regarding its prospects. Overall, the company’s recent earnings performance surpassed expectations, showcasing a solid 3% sales growth and a promising outlook for its growth portfolio, which could help restore investor confidence if it continues to outperform legacy offerings.

Consensus

Mixed

Valuation

Undervalued

Similar

Eli Lilly, LLY

DON'T BUY

Doesn't expect much growth, plus there are some issues.

DON'T BUY

New drug failed and generic drug companies getting into their products. Market share will probably shrink.

TOP PICK

Decent upside potential. Close to a decent technical support. Relatively cheap.

PAST TOP PICK

(Was a top pick on Apr 4 down 11%) Still likes.

DON'T BUY

Very reasonable valuation. Patents are coming off. Prefers Pfizer.

TOP PICK

Has had some negative occurances. At a good price.

BUY

18 X next years earnings makes it very attractive.

TOP PICK

(Was a top pick on Dec 17 up 15%) At a historic low.

DON'T BUY

Broke through a technical base. Generics are giving some tough competition.

TOP PICK

Restructured. In a temporary downturn.

BUY

Good upside potential.

DON'T BUY

Not a fan at this time. Patent expiries coming up. Prefers Pfizer.

Showing 211 to 222 of 222 entries

Most Recent Experts

Kevin Simpson

Capital Wealth Planning

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Bryn Talkington

Requisite Capital Management

Brian Madden

First Avenue Investment Counsel

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Bristol Myers Squibb (BMY)